MEDIUMRegulatoryTier 1
Her Dentist Recommends a No-Drill Cavity Treatment as Its Maker Heads for an IPO. Medicare May Not Pay a Cent
Source24/7 Wall St.Tier 1Mainstream Media
Originally at news.google.com
Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.
Why it matters for dental
Medicare still classifies the new no-drill peptide product as routine dental care, so Original Medicare and Medigap will not pay; practice owners and billing staff need to confirm patient coverage and set cash-pay expectations before offering Curodont.
Key points
- Medicare.gov states that routine cavity treatment, including a brush-on peptide, falls under the dental exclusion, so Original Medicare Parts A and B will not cover Curodont.
- vVardis filed for a U.S. IPO on October 9, 2026, with Renaissance Capital estimating a potential $200 million raise.
- Medicare Advantage plans may cover Curodont only if the specific plan’s dental benefit lists the product code and network rules allow it.
- Patients can switch from Medigap Plan G to a Medicare Advantage plan during open enrollment and retain a one-time 12-month trial right to return to Medigap without medical underwriting.
Who should care
OwnerStaff
Read the original on Media: Dental policy & coverage
Full reporting and any paywall content live on news.google.com. We summarize and score; we do not republish.